# TAXIS PHARMACEUTICALS, INC.: Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | TAXIS PHARMACEUTICALS, INC. |
| Location | MONMOUTH JUNCTION, NJ |
| Project | Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa |
| Project number | 5R44AI174351-03 |
| Mechanism | R44 |
| Institute | National Institute of Allergy and Infectious Diseases |
| Award | $875,798 |
| Awarded | 2026-09-11 |
| Project period | 2024-05-01 to 2027-04-30 |
| UEI | C2NWS2FZS5F5 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11308324). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.